Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Cancer Research Communications|2023Cited by 19
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).Amanda Psyrri, David L. Rimm, Myrto Moutafi et al.|Journal of Clinical Oncology|2021Cited by 2
Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Supplementary Figure 4 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0